熱門資訊> 正文
Mereo BioPharma集团GAAP每股收益为-0.02美元
2024-08-13 21:03
- Mereo BioPharma Group press release (NASDAQ:MREO): Q2 GAAP EPS of -$0.02.
- As of June 30, 2024, the Company had cash and cash equivalents of $87.4 million, compared to $57.4 million as of December 31, 2023.
-
More on Mereo BioPharma Group
- Mereo BioPharma: Positioned For Potential Breakthroughs
- Baird starts Mereo at outperform, sees alvelestat as underappreciated
- Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
- Seeking Alpha’s Quant Rating on Mereo BioPharma Group
- Historical earnings data for Mereo BioPharma Group
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。